We previously reported that, in various cancers excluding HCC, the median overall survival (OS) of patients who experienced any irAEs was significantly longer than that of patients without irAEs, and that the incidence of immune-related liver injury was significantly higher in patients treated with anti-CTLA-4 agents [3]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.